A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International Clinical Psychopharmacology 2008, 23: 269-275. PMID: 18703936, DOI: 10.1097/yic.0b013e328301a74c.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating Scale scoreMajor depressive disorderDepression Rating Scale scoresHamilton Anxiety ScaleRating Scale scoresPlacebo groupDepressive disorderScale scoreCGI improvement scoreCombination of quetiapinePlacebo-controlled trialClinical global improvementWeeks of treatmentOnset of actionMixed effects linear regressionQuetiapine augmentationAnxiety ScaleFluoxetine groupFluoxetine treatmentCGI scoresImproved sleepMixed effects regressionInsomnia scoresQuetiapineFluoxetineShort-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study
Mathew SJ, Garakani A, Reinhard JF, Oshana S, Donahue S. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: A 28-day, open-label study. Clinical Therapeutics 2008, 30: 1658-1666. PMID: 18840371, DOI: 10.1016/j.clinthera.2008.09.006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Anxiety AgentsAnxiety DisordersDiagnostic and Statistical Manual of Mental DisordersDrug Administration ScheduleFemaleHumansMaleMiddle AgedPiperazinesPsychiatric Status Rating ScalesSerotonin 5-HT1 Receptor AgonistsSerotonin Receptor AgonistsSingle-Blind MethodSulfonamidesSurveys and QuestionnairesTreatment OutcomeConceptsGeneralized anxiety disorderShort-term tolerabilityAdverse eventsPRX-00023Hamilton Anxiety Rating Scale scoresVital signsResponse criteriaAnxiety disordersTotal scoreOpen-label studySerotonin 1A agonistSingle-blind placeboAnxiety Rating Scale scoresSerious adverse eventsStudy end pointInfluenza-like symptomsOpen-label treatmentPrimary outcome measureDiagnosis of GADRating Scale scoresEnd point changeSample of patientsSerotonin 1A receptorPremature ventricular contractionsSelective partial agonist